| Phase 110 trials |
|
Phase 1
|
NCT07283640 |
Nov 2026 → Aug 2029 expected |
B-lymphoblastic leukemia/lymphoma MLL rearranged |
M.D. Anderson Cancer Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07498465 |
Sep 2026 → Nov 2028 |
childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, mixed phenotype acute leukemia |
Children's Oncology Group |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT07052994 |
May 2026 |
childhood leukemia |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT06575296 |
Dec 2024 → Apr 2028 expected |
acute leukemia of ambiguous lineage, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia |
City of Hope Medical Center |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06313437 |
Dec 2024 → Mar 2027 expected |
acute myeloid leukemia |
Dana-Farber Cancer Institute |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05886049 |
Jun 2024 → Dec 2027 expected |
acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, MLL gene rearrangement |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06177067 |
Apr 2024 → Oct 2026 expected |
acute leukemia of ambiguous lineage |
St. Jude Children's Research Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06222580 |
Feb 2024 → Jan 2027 expected |
acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, FLT3 internal tandem duplication, acute myeloid leukemia, MLL gene rearrangement |
Uma Borate |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05406817 |
Aug 2022 → Nov 2024 |
acute leukemia |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05326516 |
Mar 2022 → Jul 2024 |
acute lymphoblastic leukemia, acute undifferentiated leukemia, mixed phenotype acute leukemia |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT07356154 |
Jan 2026 → Jan 2029 expected |
acute lymphoblastic leukemia, mixed phenotype acute leukemia |
Memorial Sloan Kettering Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06284486 |
Sep 2024 → Dec 2026 expected |
acute myeloid leukemia |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05731947 |
Apr 2023 → Jun 2025 |
colorectal cancer |
Syndax Pharmaceuticals |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT04065399 |
Nov 2019 → Dec 2027 expected |
acute lymphoblastic leukemia, mixed phenotype acute leukemia |
Syndax Pharmaceuticals |
Recruiting
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT07563010 |
Dec 2026 → Jun 2031 expected |
acute myeloid leukemia, disease related to hematopoietic stem cell transplant |
Center for International Blood and Marrow Transplant Research |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07636564 |
Oct 2026 → Apr 2031 expected |
B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage |
SWOG Cancer Research Network |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07686107 |
Aug 2026 → Dec 2029 expected |
acute myeloid leukemia |
Therapeutic Advances in Childhood Leukemia Consortium |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07605949 |
Jul 2026 → Jul 2028 expected |
acute myeloid leukemia |
UNC Lineberger Comprehensive Cancer Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06229912 |
Jun 2024 → Dec 2026 expected |
leukemia |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05761171 |
Jan 2024 → Dec 2027 expected |
acute lymphoblastic leukemia, mixed phenotype acute leukemia |
Children's Oncology Group |
Active not recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07211958 |
Nov 2025 → Jun 2029 expected |
acute myeloid leukemia |
Syndax Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06652438 |
Mar 2025 → Dec 2029 expected |
acute myeloid leukemia |
HOVON Foundation |
Recruiting
|
No outcome recorded
|
| Phase not stated1 trial |
| — |
NCT05918913 |
— |
— |
Syndax Pharmaceuticals |
No longer available
|
No outcome recorded
|